MedTrace Logo

Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD

NCT05572333 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2023-11-29

No results posted yet for this study

Summary

The aim of this clinical trial is to investigate the safety and tolerability of oral, once-daily EP395 administration in COPD patients for 12 weeks.

Conditions

Interventions

DRUG

EP395

Capsule for oral use

DRUG

Placebo

Capsule for oral use

Sponsors & Collaborators

  • FGK Clinical Research GmbH

    collaborator INDUSTRY

  • EpiEndo Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Sukh Dave Singh, Prof. · Medicines Evaluation Unit Ltd. (MEU), Manchester, United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-22
Primary Completion
2023-11-24
Completion
2023-11-24

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05572333 on ClinicalTrials.gov